CLAIMS

1. (Currently amended) A compound of formula (I), or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof:



(I),

wherein:

A is selected from the group consisting of , , and ;



B^1 is , and B^2 is H;

R^1 and R^2 are independently selected from the group consisting of H, CH_3, and CH_3 substituted with at least one selected from the group consisting of fluoro, chloro, cyano, hydroxyl and nitro;

R^3 is selected from the group consisting of H and CH_3;

each occurrence of R is independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, nitro, hydroxyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, and substituted phenyl;

each occurrence of m is independently selected from the group consisting of 0, 1, 2 and 3;

n is selected from the group consisting of 1, 2 and 3; and

each occurrence of p is independently selected from the group consisting of 0, 1, 2 and 3.

2. The compound of claim 1, wherein A is .

3. The compound of claim 1, wherein A is .

4. The compound of claim 1, wherein A is .

5. The compound of claim 1, wherein A is selected from the group consisting of isoindolin-2-yl, 5-fluoroisoindolin-2-yl, 5-chloroisoindolin-2-yl, 5-methoxyisoindolin-2-yl, 5-methylisoindolin-2-yl, 5-hydroxyisoindolin-2-yl, 5-cyanoisoindolin-2-yl, 4-fluoroisoindolin-2-yl, 4-chloroisoindolin-2-yl, 4-methoxyisoindolin-2-yl, 4-methylisoindolin-2-yl, 4-hydroxyisoindolin-2-yl, 4-cyanoisoindolin-2-yl, 5,6-difluoroisoindolin-2-yl, 5,6-dichloroisoindolin-2-yl, 6-chloro-5-fluoroisoindolin-2-yl, 5-chloro-6-fluoroisoindolin-2-yl, 1,2,3,4-tetrahydroquinolin-1-yl, 5-fluoro-1,2,3,4-tetrahydroquinolin-1-yl, 6-fluoro-1,2,3,4-tetrahydroquinolin-1-yl, 7-fluoro-1,2,3,4-tetrahydroquinolin-1-yl, 8-fluoro-1,2,3,4-tetrahydroquinolin-1-yl, 5-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl, 6-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl, 7-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl, 8-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl, pyrrolidin-1-yl, and 3-phenyl- pyrrolidin-1-yl.

6. The compound of claim 1, wherein B^1 is selected from the group consisting of 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 4-methoxyphenyl, 4-hydroxyphenyl, and phenyl.

7. A compound, or a salt, solvate, enantiomer, diastereoisomer or tautomer thereof, selected from the group consisting of:

N-(2-(2-Chloro-4-fluorophenyl)-2-(dimethylamino)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(2-Chloro-4-fluorophenyl)-2-(dimethylamino)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-5-fluoroisoindoline-2-carboxamide;

(S)-3-Phenyl-pyrrolidine-1-carboxylic acid [2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide;

(R)-3-Phenyl-pyrrolidine-1-carboxylic acid [2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide;

(-)-N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

(+)-N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)-6-fluoro-3,4-dihydroquinoline-1(2H)-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-3,4-dihydroquinoline-1(2H)-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-6-fluoro-3,4-dihydroquinoline-1(2H)-carboxamide;

(-)-5-Fluoro-N-(2-(4-methoxyphenyl)-2-(methylamino)ethyl)isoindoline-2-carboxamide;

(+)-5-Fluoro-N-(2-(4-methoxyphenyl)-2-(methylamino)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-hydroxyphenyl)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(dimethylamino)-2-(4-hydroxyphenyl)ethyl)-5-hydroxyisoindoline-2-carboxamide;

N-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide;

(-)-*N*-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide; and

(+)-*N*-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide.

8. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of any one of claims 1-7.

9. A compound of any one of claims 1-7and/or a pharmaceutical composition of claim 14

for use in the treatment and/or prevention of pain.

10. Use of a compound of any one of claims 1-7and/or a pharmaceutical composition of claim 14 in the manufacture of a medicament for the treatment and/or prevention of pain.

11. The use of claim 10, wherein the at least one compound is selected from the group consisting of:

N-(2-(2-Chloro-4-fluorophenyl)-2-(dimethylamino)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(2-Chloro-4-fluorophenyl)-2-(dimethylamino)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-5-fluoroisoindoline-2-carboxamide;

(S)-3-Phenyl-pyrrolidine-1-carboxylic acid [2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide;

(R)-3-Phenyl-pyrrolidine-1-carboxylic acid [2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide;

(-)-N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

(+)-N-(2-(Dimethylamino)-2-phenylethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-methoxyphenyl)ethyl)-6-fluoro-3,4-dihydroquinoline-1(2H)-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-3,4-dihydroquinoline-1(2H)-carboxamide;

N-(2-(Dimethylamino)-2-phenylethyl)-6-fluoro-3,4-dihydroquinoline-1(2H)-carboxamide;

(-)-5-Fluoro-N-(2-(4-methoxyphenyl)-2-(methylamino)ethyl)isoindoline-2-carboxamide;

(+)-5-Fluoro-N-(2-(4-methoxyphenyl)-2-(methylamino)ethyl)isoindoline-2-carboxamide;

N-(2-(Dimethylamino)-2-(4-hydroxyphenyl)ethyl)-5-fluoroisoindoline-2-carboxamide;

N-(2-(dimethylamino)-2-(4-hydroxyphenyl)ethyl)-5-hydroxyisoindoline-2-carboxamide;

N-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide;

(-)-*N*-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide; and

(+)-*N*-(2-(Methylamino)-2-phenylethyl)isoindoline-2-carboxamide.

12. The use of claim 10, wherein the at least one compound is a MOR agonist.

13. The use of claim 10, wherein the at least one compound decreases cyclic adenosine monophosphate (cAMP) levels in the subject.

14. The use of claim 10, wherein the at least one compound does not significantly induce recruitment, binding to, or association with a β-arrestin.

15. The use of claim 10, wherein the at least one compound does not significantly cause at least one side effect selected from the group consisting of tachyphylaxis, respiratory depression, constipation, nausea, emesis, withdrawal, dependence, and addiction.

16. The use of claim 10, wherein the pain comprises chronic pain, neuropathic pain, nociceptive pain, hyperalgesia, and/or allodynia.